Company Profile

Acclaim Biotechnology Inc
Profile last edited on: 2/18/2019      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3520 Plumb Street
Houston, TX 77005
   (713) 669-1898
Location: Single
Congr. District: 07
County: Harris

Public Profile

Present state unknown. Assumed out of business. Acclaim Biotechnology had developed products, therapeutics and strategies based on the receptor-mediated delivery technology. The Company used its platform technologies to develop therapeutics targeted to the liver and other tissues and organs. The lead product (CD-CS) is a patented fusion protein with a drug-metabolizing enzyme (CD) and a liver-targeting protein (CS) from the malarial parasite. The CS protein targets the surface receptors of the liver cells, while the CD enzyme converts a nontoxic prodrug to the toxic metabolite. This regimen is preferentially toxic to the proliferating tumor cells, and the non-tumor liver tissues and other organs are essentially not affected. Research conducted indicates that this approach is specific, efficiency and safe. Therefore, this product is particularly applicable for improving chemotherapy of liver cancer and liver metastasis, which affect tens of thousands of patients worldwide. Venture capitals and partners are welcome to join in developing and commercializing this novel technology

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $100,000
Project Title: Targeted Prodrug Therapy of Liver Cancers

Key People / Management

  John Y Chan

Company News

There are no news available.